By Regulatory Approvals — US FDA approves tucatinib with trastuzumab & pertuzumab for HER2+ breast cancer Oncology Central
Read the original at Regulatory Approvals ↗
Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. October 12, 2026.